Literature DB >> 6983964

Pharmacological properties of carprofen.

K M Strub, L Aeppli, R K Müller.   

Abstract

Carprofen, a new non-steroidal anti-inflammatory agent, showed marked anti-inflammatory and analgesic effects in various relevant experimental models. The analgesic activity was restricted to conditions where pain was provoked by an inflammatory process. Induction of intestinal ulcers was the only side effect recognizable in animals and occurred only after high doses. Inhibition of prostaglandin (PG) synthesis by carprofen was slight in relation to its anti-inflammatory and analgesic potency. As ulcerogenicity of non-steroidal anti-inflammatory agents is correlated with inhibition of the PG-synthesis, the insignificant impairment of the PG-synthesis in therapeutically effective doses may explain the good gastrointestinal tolerance repeatedly reported for carprofen in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6983964

Source DB:  PubMed          Journal:  Eur J Rheumatol Inflamm        ISSN: 0140-1610


  4 in total

1.  Evaluation of the analgesic efficacy and safety of carprofen.

Authors:  J E Lindenmuth; M S Clark; G E Fryer
Journal:  Anesth Prog       Date:  1989 Jul-Oct

2.  Comparative effects of carprofen, benoxaprofen and indomethacin on the development and decay phases of a carrageenan pleurisy in the rat.

Authors:  D Bradshaw; P H Franz; S J Greenham
Journal:  Agents Actions       Date:  1984-06

3.  Transcutaneous treatment with vetdrop(®) sustains the adjacent cartilage in a microfracturing joint defect model in sheep.

Authors:  M Sidler; N Fouché; I Meth; F von Hahn; B von Rechenberg; Pw Kronen
Journal:  Open Orthop J       Date:  2013-03-05

4.  Preliminary study on carprofen concentration measurements after transcutaneous treatment with Vetdrop® in a microfracture joint defect model in sheep.

Authors:  Michèle Sidler; Nathalie Fouché; Ingmar Meth; Friedrich von Hahn; Brigitte von Rechenberg; Peter W Kronen
Journal:  BMC Vet Res       Date:  2014-12-09       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.